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Abstract Renal diseases are prevalent and important.
However, despite significant strides in medicine, clinical
nephrology still relies on nonspecific and inadequate
markers such as serum creatinine and total urine protein
for monitoring and diagnosis of renal disease. In case of
glomerular renal diseases, biopsy is often necessary to
establish the diagnosis. With new developments in proteo-
mics technology, numerous studies have emerged, search-
ing for better markers of kidney disease diagnosis and/or
prognosis. Blood, urine, and renal biopsy tissue have been
explored as potential sources of biomarkers. Some interest-
ing individual or multiparametric biomarkers have been
found; however, none have yet been validated or entered
clinical practice. This review focuses on some studies of
biomarkers of glomerular renal diseases, as well as
addresses the question of which sample type(s) might be
most promising in preliminary discovery phases of candi-
date proteins.




1D-SDS-PAGE One-dimensional sodium dodecyl sul-
fate polyacrylamide gel electrophoresis
2-DE Two-dimensional electrophoresis
2DE-DIGE Two-dimensional fluorescence differ-
ence gel electrophoresis
ESI Electrospray ionization
FSGS Focal segmental glomerulosclerosis
FT-ICR Fourier transform ion cyclotron resonance
HPLC High-performance liquid chromatography
IMN Idiopathic membranous nephropathy
IT Ion trap





SELDI Surface-enhanced laser desorption/
ionization
SLE Systemic lupus erythematosus
TOF Time of flight
Q Quadrupole
Introduction
Chronic kidney disease (CKD) is a worldwide health
problem. Based on the data from the USA, the prevalence of
end-stage renal disease increased from 86,354 in 1983 to
506,256 in 2006 [1]. The prevalence of CKD when using the
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definition of glomerular filtration rate (GFR) <60 ml/min per
1.73 m2 is 4.7% or 8.3 million in the USA [2]. Renal
diseases are thus highly prevalent and important; however,
there are few diagnostic markers of kidney disease, and in
many cases one must rely on a renal biopsy, particularly in
the case of glomerular renal diseases. While biopsy is
considered the gold standard diagnostic test, it is associated
with multiple problems. First and foremost, it carries risks to
the patient including hemorrhage, pain, and even death [3,
4]. It is costly due to postbiopsy monitoring or additional
procedures required if complications occur. Biopsy may be
contraindicated in uncontrolled hypertension, coagulopathy,
pregnancy, or in patients with a single kidney. Finally,
biopsy may not be adequate or representative of the disease
in the rest of the kidney. Furthermore, there are few clinical
or biochemical parameters to guide treatment or to inform
prognosis. Main markers used in clinical practice are serum
creatinine and total urine protein. Serum creatinine is a late
marker of renal injury and suffers from several other
drawbacks including the following: it can be used to estimate
GFR only in steady state, it varies with diet and muscle
mass, and creatinine undergoes increased tubular secretion in
advanced stages of kidney disease. Urine protein is one of
the best predictors of progression of renal disease, but it is
nonspecific, and the levels that predict increased risk are
different in distinct diseases (e.g., 1 g/day of proteinuria in
IgA nephropathy carries higher risk of progression than the
same degree of proteinuria in membranous nephropathy) [5,
6]. In other words, novel markers of renal disease diagnosis
or progression are desperately needed.
Biological fluids such as urine and blood, as well as
renal tissues, contain thousands of proteins that undergo
changes in response to disease. The emergence of proteo-
mics (a large-scale study of proteins and their function and
structure) and development of methods to simultaneously
analyze hundreds or thousands of proteins have opened the
door to potentially capturing these disease or state-specific
changes. However, after several years of research and
numerous papers in this field, only a few proteins have
emerged as potential biomarkers, and none have influenced
clinical practice. This review will highlight some basic
concepts in mass spectrometry and describe some studies
with particular focus on glomerular diseases, as well as
tackle the question of which type of sample may be most
promising in uncovering candidate biomarkers in kidney
diseases.
Proteomics Techniques
Whichever sample type is analyzed, complex protein
mixtures must be fractionated to increase detection of
low-abundance proteins [7]. Protein separations can be
achieved by one-dimensional sodium dodecyl sulfate
polyacrylamide gel electrophoresis (1D-SDS-PAGE), two-
dimensional electrophoresis (2-DE), or capillary electro-
phoresis (CE). 1D-SDS-PAGE separates proteins based on
mass, CE separates them based on isoelectric point, and
2-DE separates them in two dimensions using both mass
and isoelectric point. The resolution of 2-DE is poor. CE has a
much higher resolution, being able to resolve 400–2,000
peptides per run. CE can be coupled to the MS and has been
used extensively in proteomic studies of renal disease.
Unfortunately, this technique misses small peptides [8]. A
variation of two-dimensional separation has been developed
which is called two-dimensional fluorescence difference gel
electrophoresis (2DE-DIGE) and which relies on fluorescent
dyes for more accurate quantification. Peptide separation can
be achieved using high-performance liquid chromatography
(HPLC), which can also be coupled directly to the mass
spectrometer (MS). HPLC separates peptides based on
charge and/or hydrophobicity.
Mass Spectrometry
A mass spectrometer contains an ion source, an analyzer,
and a detector. An ionization source may be matrix-assisted
laser desorption/ionization (MALDI), surface-enhanced
laser desorption/ionization (SELDI), or electrospray ioniza-
tion (ESI). MALDI and SELDI are soft ionization techni-
ques used in mass spectrometry to analyze biomolecules
that tend to be fragile and fragment when ionized by more
conventional ionization methods. They require an organic
matrix to allow analyte ionization by laser pulses. Mostly
singly charged ions are generated in this way, and they are
easier to work with, but both techniques have been
criticized for lack of reproducibility and sensitivity to
sample collection and processing procedures [9]. ESI and
MALDI were awarded the Nobel Prize in Chemistry in
2002. In the case of ESI, the end of a liquid chromatog-
raphy column or a metal needle is held at a high electrical
potential (several kilovolts) with respect to the entrance of
the mass spectrometer. The liquid effluent containing the
peptides that are eluting from the chromatography column
is thereby electrostatically dispersed. This generates highly
charged droplets, which are normally positively charged in
proteomics experiments. Once the droplets are airborne, the
solvent evaporates, which increases the charge density of
the droplets. Desolvated ions are generated by desorption of
analyte ions from the droplet surface due to repetitive
droplet fission until each droplet contains only one analyte
ion. Mass analyzers include: time of flight (TOF), quadru-
pole (Q), ion trap (IT), and Fourier transform ion cyclotron
resonance. Hybrids of these devices can be employed in
sequential combination, and this is known as MS/MS (or
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tandem mass spectrometry). Examples of such include:
Q-Q-Q, Q-TOF, TOF-TOF, etc. In this case, the precur-
sor ion selected from the first MS scan is fragmented by
collision-induced dissociation with an inert gas, and
subsequent product ions are detected by the second mass
analyzer. MALDI is typically coupled to TOF due to its
pulsatile generation of ions which can enter the drift tube
and travel to the detector. ESI is coupled with Q or Q-
TOF, although the newer linear ion traps (LTQ) coupled
to the Orbitrap analyzer offer superior resolution and
high mass accuracy.
MS analysis generates data which need to be pro-
cessed by sophisticated computer algorithms and which
will ultimately lead to peptide identification. There are
two main approaches used in peptide identification: de
novo sequencing and database searching. De novo
sequencing is an older sequencing method applied when
there is no knowledge of sample at hand. This method
depends critically on the quality of the data generated
and was associated with multiple problems. The most
commonly used identification method nowadays is
database searching. The reason for its success is that
only an infinitesimal fraction of the possible peptide
amino acid sequences actually occur in nature [10]. A
peptide fragment spectrum might not have all the
information to unambiguously derive the entire amino
acid sequence, but it might have enough information to
match it to a peptide sequence in database based on
observed and expected fragment patterns. Several search-
ing algorithms to be used with MS/MS spectral data have
been developed and they include: Mascot, Sequest,
PeptideSearch, X!Tandem, etc. The list of proteins
generated is accompanied by a score based on the peptide
number and confidence in identified peptides.
Renal Proteomic Studies
The quest for biomarkers of renal disease diagnosis or
progression has been expanded to different sample types
including: blood, urine, and tissue from renal biopsies.
Which of these sample types should be explored in
preliminary experiments, and which one holds most
promise as a source of biomarkers? Should researchers
use more than one sample type in arriving at the answer?
We present some facts and opinions based on the published
literature, in an attempt to address these questions. Table 1
summarizes the most important glomerular disease bio-
markers mentioned in this review.
Blood Proteomics
Blood has emerged as a gold mine for biomarkers in a
variety of different fields. It has intimate contact with every
tissue in the body, thus carrying subliminal messages in the
form of proteins or peptides. Concentrations of plasma
proteins span 10 orders of magnitude [11]. This means that
no single experimental approach would give insight into all
the proteins present in blood. Furthermore, the search for
low-abundance proteins, which represent the most plausible
source of biomarkers, is challenging [12]. To illustrate this
point, we look at several studies reporting albumin frag-
ments as potential biomarkers of disease. One of these
studies examined differential protein expression in children
with genetic focal segmental glomerulosclerosis (FSGS)
versus those with idiopathic FSGS [13]. The authors used
2-DE followed by MALDI-TOF and ESI-MS/MS, and they
pooled serum samples from patients in each group. This
methodology precluded the discovery of low-abundance
Table 1 The most promising proteomic biomarkers of glomerular renal diseases described in this review
Biomarker Disease Technique used Reference
Blood
IgG4 Ab to M-phospholipase A2 receptor IMN HPLC-MS/MS [22]
Albumin sulfonation on Cys34 residue FSGS LC-ESI-MS/MS [21]




Collagen I fragments Diabetic nephropathy CE-MS [29]
E-cadherin Diabetics with proteinuria 2D-DIGE; MALDI-TOF [31]
Hepcidin-20 Lupus nephritis Columns ≤30 kDa; SELDI-TOF [33]
Renal tissue
Apolipoprotein E MPGN-II? Laser microdissection; LTQ-Orbitrap [36]
C7, C8 fragments MPGN-II vs IC-MPGN [36]
Ab antibody, IMN idiopathic membranous nephropathy, FSGS focal segmental glomerulosclerosis, MPGN-II membranoproliferative
glomerulonephritis type II, IC-MPGN immune-complex-mediated membranoproliferative glomerulonephritis
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proteins, and in fact, albumin fragments differentiated
genetic FSGS from idiopathic FSGS. While it is plausible
that a distinct albumin form exists in blood of these
subjects, as the authors speculate, it is tempting to attribute
this finding to high albumin abundance alone. Additionally,
serum is subject to endoproteolytic and exoproteolytic
activity, and this result could be a side effect of this
potential artifact [14, 15]. Similarly, albumin fragments are
reported in several urine proteomic studies [16], and this is
further discussed below. There are several ways of
resolving the problem associated with high-abundance
proteins. One method used was magnetic bead technology
focusing on peptides less than 7 kDa [17]. Magnetic bead-
assisted serum peptide capture was followed by MALDI-
TOF or ESI-IT MS/MS in patients with IgA nephropathy
and healthy controls. Out of 92 peptides, five were able to
distinguish the two groups, and three of these were
increased in IgA nephropathy and belonged to fibrinogen
alpha chain. The remaining two peptides were higher in the
control group and were identified as C3f fragment and
kininogen-1 light chain. Several other approaches have
been developed to deplete abundant proteins by affinity
chromatography. Unfortunately, this depletion is not quan-
titative [18]. Furthermore, elimination of abundant proteins
depletes additional, potentially useful molecules, as illus-
trated by a study where 814 proteins were codepleted with
albumin [19]. Instead of trying to eliminate albumin, some
investigators took advantage of this highly abundant
protein. Albumin had been shown in vitro to be oxidized
during oxidative stress [20]. Musante and colleagues used
LC-ESI-MS/MS to analyze plasma albumin from patients
with active FSGS or other glomerular disorders including
IgA nephropathy, idiopathic membranous nephropathy
(IMN), or normal controls and determined that albumin
oxidation was dramatic only in active FSGS [21]. This was
shown by demonstrating sulfonated albumin on residue
Cys34. Given that this finding was not only specific for
FSGS but was also present during active disease, oxidized
albumin may represent a potential biomarker of disease
activity as well as diagnosis. Future validation studies of
this particular molecule would be of interest.
Besides the “shotgun” (discovery-based) proteomic
approaches investigating human sera in relation to renal
disease, other more focused questions have yielded impor-
tant and novel information. Beck and colleagues blotted
normal renal glomeruli with sera from patients with IMN
[22]. They identified a band and with the help of MS were
able to delineate the identity of glomerular antigen that was
bound by an antibody from sera of 70% of patients with
IMN, but none of the secondary membranous cases, FSGS,
diabetic nephropathy, or normal controls. This antigen was
M-type phospholipase A2 receptor, which is highly
expressed in glomerular podocytes and which was bound
by an IgG4 antibody. This discovery has led to new insights
into the pathogenesis of this disease and may facilitate
development of novel serologic tests for diagnosis of IMN
or monitoring disease activity.
Urine Proteomics
The most promising fluid as a future source of biomarkers
of renal disease is urine. What makes urine particularly
attractive is that it can be obtained in a noninvasive fashion,
it is present in abundance and can be collected as often as
needed without any risks to the patient. Furthermore, urine
proteomic profile appears to be stable for many years when
urine is stored at −80°C [23]. Urine is produced by the
kidney, and its final proteome is further influenced by few
additional downstream organs. Urine contains ≤150 mg/day
of total protein, 70% of which is derived from the kidney,
with 30% originating from plasma [24]. Unfortunately,
there are disadvantages to using urine which have hindered
the discovery of biomarkers. A universal method for urine
collection and storage has not yet been developed, although
this has been the focus of several international organiza-
tions including the Human Kidney and Proteome Project
and European Kidney and Urinary Proteomics. Urinary
proteome is influenced by exercise [25], diet [23], time of
day when urine is collected [26, 27], and sex [27]. Similar
to blood, urine has a wide dynamic range of protein
concentrations, with albumin being the most abundant
protein [28]. This becomes an even greater problem in
patients who have higher grades of proteinuria, such as
all patients with glomerular diseases. The high-
abundance proteins dominate the proteome, with low-
abundance ones being potentially more informative as
biomarkers of disease. Not surprisingly, some of the
same problems associated with blood proteomics can be
reiterated here. Candiano and colleagues employed 2-DE
and MALDI-TOF to investigate urines of children with
FSGS, minimal-change disease, IMN, and normal con-
trols [16]. The main differences detected between cases
and controls were fragments of albumin and alpha-1-
antitrypsin. While the author's interpretation of an existing
novel albumin adduct is plausible and analogous to the
case of FSGS described above, both albumin and alpha-1-
antitrypsin fragments could be there solely due to higher
concentration of these highly abundant proteins in patients
with higher than normal proteinuria. Several proteomic
studies examining biomarkers in urine of patients with
diabetes mellitus have been published. One of the studies
used CE-MS to define peptide sets associated with
diabetes and diabetic nephropathy, as well as markers that
could differentiate diabetic nephropathy from other glo-
merular renal diseases with sensitivity and specificity
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around 81–97% [29]. Several peptides correlated with
fragments of collagen I, known to accumulate in kidneys
of patients with diabetic nephropathy. These fragments
were lower in diabetic patients than those with other renal
diseases, inviting a hypothesis that decreased clearance
and cleavage of this product might lead to its accumulation
in the kidney. Contrary to this, a different group studying
urine of patients with diabetic nephropathy, making
comparison to other renal diseases or normal controls,
used MALDI-TOF/TOF and isolated fragments of
collagen-alpha-5 and collagen-alpha-I which were high in
the diseased states, compared to normal controls [30]. This
difference in findings could be due to sample preparation,
variability in the two cohorts studied, or reasons that are
not yet apparent. In terms of other markers of extracellular
matrix, urine E-cadherin was discovered to be a potential
biomarker reliably distinguishing between diabetics with
microalbuminuria or macroalbuminuria from healthy con-
trols and diabetics with normoalbuminuria [31]. The
authors used 2DE-DIGE followed by MALDI-TOF, and
results were confirmed by ELISA and Western blotting.
Increased levels of soluble urine E-cadherin could be a
sign of epithelial-to-mesenchymal transition, described in
the process leading to renal fibrosis [32]. Not surprisingly,
among their top hits, these authors also identified albumin,
uromodulin, and retinol-binding protein, all highly abun-
dant urine proteins, likely correlating with the degree of
proteinuria.
Lupus nephritis represents a conglomeration of glomer-
ular renal diseases caused by systemic lupus erythematosus,
which would greatly benefit from the ability to predict
flares or monitor therapeutic response. One longitudinal
study ambitiously evaluated the urine proteome from 19
patients at many different time points [33]. To uncover
lower molecular weight proteins, the authors fractionated
urine using columns with cutoff size of 30 kDa. This was
followed by SELDI-TOF. The most interesting protein
isolated increased 4 months before the flares and was
identified as an isoform of hepcidin. Immunohistochemistry
of renal tissue confirmed hepcidin staining of infiltrating
leukocytes in patients with active disease. This finding
provides an interesting molecule that could potentially be
evaluated in future studies. Nonetheless, even when using
30-kDa cutoff columns, the authors found albumin and
alpha-1-antitrypsin fragments which were significantly
elevated during flares. Another study cross-sectionally
compared patients with active versus those with inactive
lupus nephritis [34]. They identified two peaks that could
discriminate between active and inactive disease with 92%
sensitivity and specificity and confirmed findings in a
separate small cohort of cases. The identities of these two
peaks are unknown, and their value in monitoring disease
activity has not been validated.
Numerous other studies of urine proteomics addressing
various glomerular and other renal diseases have been
published. Unfortunately, none of these have been validated
in large clinical trials or have influenced clinical practice.
Thus, urine represents an attractive source of biomarkers
which may not be ready yet for the prime time.
Renal Tissue Proteomics
Renal tissue represents an important source of potential
biomarkers, particularly in the preliminary, exploratory
phases. However, this sample type is not ideal for ultimate
disease monitoring or diagnosis, since it is difficult to
obtain, particularly when repetitive sampling is needed.
Patient risks associated with kidney biopsy have been
outlined above. Tissue proteomics has been advanced by
technical developments allowing analysis of formalin-fixed,
paraffin-embedded tissues [35]. In one of the most
interesting and original approaches, Sethi and colleagues
performed laser microdissection of glomeruli in membra-
noproliferative glomerulonephritis type II (MPGN-II) [36].
Immune-complex-mediated MPGN cases and implantation
biopsies of living donors served as controls. The deposits
were subjected to LC-MS/MS using LTQ-Orbitrap. Not
surprisingly, proteins identified with the highest confidence
comprised the alternative complement cascade, known to
be causative in MPGN-II. However, terminal complement
components were also identified in MPGN-II glomeruli,
suggesting excessive fluid-phase production of the terminal
complement complex. Finally, apolipoprotein E was repro-
ducibly present in glomeruli of patients with MPGN-II, and
it remains unclear whether this protein is important in the
pathogenesis of this disorder. If proven to be important, the
search for apolipoprotein E may be warranted in urine.
Unfortunately, despite high resolution and accuracy of the
techniques used, no quantification was applied, thus
making it difficult to draw conclusions regarding relative
abundances of these proteins in MPGN-II. Another study of
renal graft interstitial fibrosis and tubular atrophy took
advantage of the biopsy tissue to derive lists of proteins
differentiating various histopathologies associated with
interstitial fibrosis and tubular atrophy and formulated
hypothesis-generating mechanisms [37]. They used LC-
MS (LTQ) followed by single-reaction ion monitoring for
verification of top candidates. Renal tissue is useful when
used in conjunction with other exploratory platforms to
verify findings or in well-designed questions addressing
specific disease entity or specific renal compartments.
Lastly, various groups are beginning to use cell cultures
in the hope of defining potential biomarkers in a controlled
in vitro setting where protein quantification is more readily
performed. These systems do not suffer from some of the
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shortcomings of fluid proteomics already discussed and
could be a preliminary step to finding potential secretory
markers of interest that could inform subsequent rigorous
validation studies in urine or blood. Additionally, these
studies could lead to further hypothesis-generating mecha-
nisms of renal diseases or processes involved in normal
renal physiology [38, 39] and that could be subsequently
tested in human samples.
Conclusion
Nephrology is in desperate need of biomarkers that could
assist in renal disease diagnosis or monitoring of disease
activity. Countless markers have emerged from the proteo-
mic pipeline, but none have been validated or become
available in clinical practice. It appears that the most
promising markers can come from well-designed, specific
research questions if using complex fluids or tissues and
from use of more than one fluid or tissue for verification.
Nonetheless, there is hope for discovery-based approaches
from fluids, once the sample preparation and the applica-
tions of MS technologies to these complex fluids are better
understood and once there are more reliable ways of
examining the low-abundance proteome. An alternative
approach could be the use of an indirect system, such as
cell cultures, to discover plausible candidates that could be
subsequently tested in biological fluids. The most promis-
ing fluid for ultimate monitoring of renal diseases still
appears to be urine. Aspects of proteomic study validation
have not been addressed here, but this is one of the
fundamental steps in discovering reliable biomarkers.
We conclude by mentioning that we are still struggling
to take advantage of MS as a multiparametric, quantitative
technique. Intuitively, it is highly likely that a carefully
selected panel of urinary or serum proteins should do much
better in renal disease diagnosis or prognosis than creati-
nine or total protein measurements. Hopefully, such a panel
should emerge soon.
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